September 27, 2023 10:21 AM EDT

Gilead stops another CD47 study, this time in acute myeloid leukemia

Lei Lei Wu

News Reporter

Gilead stopped a Phase III study of its CD47 antibody magrolimab in patients who have acute myeloid leukemia with TP53 mutations, the company

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

FDA approves Moderna’s next-gen Covid vaccine, with limits on most healthy people

Summit’s disappointing survival readout raises stakes for full data

Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA

Summit says bispecific misses overall survival in closely-watched lung cancer study

Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation